UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 1, 2007
INGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Georgia 000-28704 88-0429044
------- ----------- ----------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification Number)
35193 Avenue "A", Suite-C, Yucaipa, California 92399
---------------------------------------------- -----
(Address of principal executive offices) (Zip Code)
(800) 259-9622
--------------
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
1.01 Entry into a Material Definitive Agreement
The Board of Directors ("Board") of Ingen Technologies, Inc. ("Ingen")
approved Resolution 2007.12 dated August 16, 2007. The Board also approved, by
email vote known as Resolution 2007.11, an agreement with Invacare Supply Group,
Inc.
Resolution 2007.11 (referred to as a resolution, but is actually just an
email vote of the Board) approved the entry of Ingen into an exclusive
distribution agreement with Invacare Supply Group, Inc. ("ISG"). The term of the
agreement is 3 years for the sale of Ingen's Oxyview(TM), commencing August 1,
2007. The territory includes North America, South America, Europe, Asia,
Australia and New Zealand. ISG will purchase a confidential number of units
initially. The pricing of units is also confidential. The parties will set goals
for the remainder of the contract term after the first 12 months.
Resolution 2007.12 approves an agreement with MedOx, Corporation for the
provision of services for Oxyview(TM) and OxyAlert(TM) that includes
installation, training, marketing and other services for a 3 year period. The
agreement provides for per unit sold compensation as well as 2 million shares of
Ingen common stock (when and if ISG sells 1 million Oxyview(TM) units) and a
$20,000 payment by January 1, 2008.
Resolution 2007.12 also authorizes the filing of this Form 8-K with
confidential treatment of some contract terms.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: August 22, 2007 Ingen Technologies, Inc.
By: /s/ Scott R. Sand
-------------------------------------
Scott R. Sand
Chief Executive Officer and Chairman
TABLE OF EXHIBITS
(All Exhibits have been properly signed by the parties.
Original agreements are filed in our offices)
EXHIBIT NO. DESCRIPTION
99.1 Ingen Technologies, Inc. Board Resolution 2007.12.
99.2 INGEN TECHNOLOGIES & INVACARE SUPPLY GROUP - Medical Supply
Master Distribution Agreement (8-K EXHIBIT ONLY), executed by
Ingen on August 13, 2007 and by ISG on August 14, 2007.
99.3 Agreement between Ingen Technologies, Inc. and MedOx, Corporation
dated August 1, 2007.